Literature DB >> 16214602

Cholangiocarcinoma.

Shahid A Khan1, Howard C Thomas, Brian R Davidson, Simon D Taylor-Robinson.   

Abstract

Cholangiocarcinoma is a devastating malignancy that presents late, is notoriously difficult to diagnose, and is associated with a high mortality. The incidence of intrahepatic cholangiocarcinoma is increasing worldwide. The cause for this rise is unclear, although it could be related to an interplay between predisposing genetic factors and environmental triggers. MRI and CT with endoscopic ultrasound and PET provide useful diagnostic information in certain patients. Surgical resection is the only chance for cure, with results depending on careful technique and patient selection. Data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy. Chemotherapy and radiotherapy have been ineffective for patients with inoperable tumours. For most of these patients biliary drainage is the mainstay of palliation. However, controversy exists over the type and positioning of biliary stents. Photodynamic treatment is a new palliative technique that might improve quality of life.

Entities:  

Mesh:

Year:  2005        PMID: 16214602     DOI: 10.1016/S0140-6736(05)67530-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  414 in total

1.  Outcomes following resection of intrahepatic cholangiocarcinoma.

Authors:  Parissa Tabrizian; Ghalib Jibara; Jaclyn F Hechtman; Bernardo Franssen; Daniel M Labow; Myron E Schwartz; Swan N Thung; Umut Sarpel
Journal:  HPB (Oxford)       Date:  2014-11-14       Impact factor: 3.647

2.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 3.  [Liver transplantation for hilar cholangiocarcinoma].

Authors:  F Rauchfuss; F Utess; S Schüle; Y Dittmar; H Scheuerlein; U Settmacher
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

4.  Brain metastasis and leptomeningeal carcinomatosis in a patient with cholangiocarcinoma.

Authors:  Basem M William; Jean L Grem
Journal:  Gastrointest Cancer Res       Date:  2011-07

5.  Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.

Authors:  Tongsen Zheng; Jiabei Wang; Xi Chen; Xianzhi Meng; Xuan Song; Zhaoyang Lu; Hongchi Jiang; Lianxin Liu
Journal:  Tumour Biol       Date:  2010-04-27

6.  Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically.

Authors:  Antonio Franchitto; Alessia Torrice; Rossella Semeraro; Cristina Napoli; Gennaro Nuzzo; Felice Giuliante; Gianfranco Alpini; Guido Carpino; Pasquale Bartolomeo Berloco; Luciano Izzo; Antonio Bolognese; Paolo Onori; Anastasia Renzi; Alfredo Cantafora; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 7.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

Review 8.  Transarterial therapies for the treatment of intrahepatic cholangiocarcinoma.

Authors:  Joseph J Zechlinski; William S Rilling
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 9.  Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status.

Authors:  Reiji Sugita
Journal:  World J Hepatol       Date:  2013-12-27

10.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.